Jun. 7, 2010 (Business Wire) -- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 9th Annual Needham Healthcare Conference being held in the New York Palace Hotel, New York City from June 9-10, 2010.
Stephen M. Simes, BioSante’s president & chief executive officer, will speak on Wednesday, June 9 at 11:20 am ET. Mr. Simes will provide a status update on BioSante’s lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as the Company’s portfolio of cancer vaccines in clinical development with Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. A live audio webcast of Mr. Simes’ remarks may be accessed at http://www.wsw.com/webcast/needham38/bpa/ and a replay will be available at the same link.
About the Needham Healthcare Conference
The 9th Annual Needham Healthcare Conference will be held June 9-10, 2010 at The New York Palace Hotel in New York City. The Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. Over the course of two days, attendees participate in moderated company presentations, as well as expert panels of clinical and industry professionals.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
